Committee Composition

  Audit Nominating and Governance Compensation Strategic
John T. Henderson, M.D. Chairman of the Board Independent Director   Member of Nominating and Governance Committee Member of Compensation Committee Committee Chair for Strategic Committee
Lawrence C. Best Independent Director Member of Audit Committee     Member of Strategic Committee
Lawrence Best Director
Chairman and Founder of OXO Capital LLC

Lawrence C. Best, a Director of the Company since September 2009, joined Boston Scientific Corporation in 1992 and served for 15 years as the Executive Vice President-Finance & Administration and Chief Financial Officer. Prior to joining Boston Scientific, Mr. Best was a partner in the accounting firm of Ernst & Young, where he specialized in serving multinational companies in the high technology and life sciences fields. He served a two-year fellowship at the SEC from 1979 to 1981 and a one-year term as a White House-appointed Presidential Exchange Executive in Washington, D.C. He currently serves on the Board of Directors of Haemonetics Corp. and is a founding director of the President's Council at Massachusetts General Hospital. Mr. Best received a B.B.A. degree from Kent State University.
Heiner Dreismann, Ph.D. Independent Director     Committee Chair for Compensation Committee Member of Strategic Committee
Walter Gilbert, Ph.D. Independent Director     Member of Compensation Committee  
Dennis Langer, M.D, J.D. Independent Director Member of Audit Committee Committee Chair for Nominating and Governance Committee    
S. Louise Phanstiel Independent Director Committee Chair for Audit Committee Member of Nominating and Governance Committee    
Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member Independent Director = Independent Director

Stock transaction information provided by EDGAR Online. Myriad Genetics, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

Stock Quote (NASDAQ:MYGN)

+ 0.46
Previous Close:
Day High:
Day Low:
52 Week High:
52 Week Low:
4:00 PM ET on Jul 23, 2014
Delayed at least 20 minutes.
Provided by eSignal.

Investor Contact

Scott Gleason
(801) 584-1143

Media Contact

Ron Rogers
Corporate Communications and Media Relations
(801) 584-3065